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iABSTRACT
Background: According to prescribing information
for rheumatoid arthritis (RA) treatments in the United
States, infliximab should be administered at weeks 1, 2,
6, and then every 8 weeks starting at a 3-mg/kg dose,
with flexible dosing up to 10 mg/kg and/or every 4
weeks based on clinical response.
Objective:This study evaluated dosing and intervals
of the first 12 infliximab infusions in patients with RA
across multiple large administrative databases.
Methods: Data were obtained from 4 databases:
HealthCore Integrated Research Database (HIRD),
IMS LifeLink Health Plan Claims Database (IMS Life-
link), Premier Perspective Database (PPD), and
Wolters Kluwer Pharma Solutions (WKPS). Patients
were aged18 years, diagnosed with RA, and naive to
biologic therapy. Patients with other select inflamma-
tory conditions were excluded. The induction period
included infusions 1 through 3; the maintenance pe-
riod included infusions 4 through 12.
Results: Observed dosing patterns from the
HIRD, IMS LifeLink, PPD, and WKPS databases
demonstrated minimal dose increases from the first
infusion (93.5, 103.3, 58.8, and 73.2 mg, respec-
tively) and from the first maintenance infusion (69.1,
64.3, 45.7, and 45.7 mg, respectively) to the highest
dose during the first 12 infusions. The mean number
of days between infusions in the maintenance period
ranged from 53.3 to 63.5 in HIRD, 53.7 to 60.3 in
IMS LifeLink, 53.4 to 59.4 in PPD, and 52.3 to 55.0
in the WKPS database.
Conclusion: Data from multiple databases of pa-
tients with RA suggest that, in clinical practice, inf-
liximab dosing and intervals are consistent with
FDA prescribing information and remain
relatively stable during the first 12 infusions. (Clin
2286Ther. 2012;34:2286–2292) © 2012 Elsevier HS
Journals, Inc.
Key words: dosing, infliximab, infusion intervals,
rheumatoid arthritis.
INTRODUCTION
Guidelines for the use of nonbiologic and biologic dis-
ease-modifying antirheumatic drugs (DMARDs) for the
treatment of rheumatoid arthritis (RA) were most re-
cently updated by the American College of Rheumatol-
ogy in 2012.1 Treatment with nonbiologic and biologic
MARDs should target lowdisease activity or remission.
he use of tumor necrosis factor (TNF)- inhibitors, the
argest therapeutic class of biologic DMARDs, is recom-
ended in patients with new RA, high disease activity,
nd poor prognostic features and in patients with estab-
ished RA and moderate or high disease activity, after 3
onths of nonbiologic DMARD treatment.1 Infliximab
s a commonly used TNF- inhibitor administered as an
ntravenous infusion.2
Infliximab has been shown to reduce signs and
symptoms of RA, inhibit the progression of structural
damage, and improve physical function in patients
with moderately to severely active RA.2 For this indi-
cation, the US Food and Drug Administration (FDA)
recommends that infliximab, in combination with
methotrexate, be administered at 3 mg/kg at weeks 0,
2, and 6 (induction period) and every 8 weeks thereaf-
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sponse, the dose may be increased to as much as 10
mg/kg, and maintenance intervals may be decreased to
as frequently as every 4 weeks.2 Approximately 10%
of patients treated with infliximab through 1 to 2 years
may develop antibodies to infliximab.2 These antibod-
es may reduce clinical effect and lead to a need for
ncreased dosing.3
To date, several published studies have evaluated
dosing patterns of TNF- inhibitors in clinical studies,
patient registries, physician chart reviews, and medical
claims databases.4–13 The current evidence on inflix-
mab generally demonstrates relatively small dose in-
reases and limited increases in infusion frequency, all
f which have been within FDA-recommended dosing.
garwal et al5 reported a mean dose increase from
3.15 to 4.39 mg/kg in patients with RA receiving inf-
liximab from 2 US hospital infusion centers. In that
same study, patients with a decreased infusion interval
had a mean interval of 7.0 weeks compared with 8.7
weeks in those without a decreased infusion interval.5
Stern and Wolfe,6 after reviewing infusion records
from 2 large rheumatology practices, reported an ini-
tial mean dose of 3.6 mg/kg, increasing to 4.9 mg/kg at
1 year and to 5.1 mg/kg at 2 years. In addition, they
reported that 95% of infusions were given at 8-week
intervals.6 Retrospective analyses of medical claims
ata have reported similar results. Harley et al7 re-
ported that the mean infliximab dose increased from
276 mg at initiation to 329 mg at final infusion, and
Etemad et al8 reported that the mean dose increased
rom 2.8 vials (1 vial  100 mg) at initiation to 3.6
ials at final infusion.
Using multiple US-specific data sources with similar
tudy designs, the present study sought to corroborate
nfliximab dosing patterns and infusion intervals in pa-
ients with RA in clinical practice. The study evaluated
oth the quantity of dose per infusion (in milligrams)
nd the number of days between the first 12 infliximab
nfusions in patients with RA across 4 large databases.
PATIENTS AND METHODS
Study Design and Patients
Data were obtained separately from 4 administra-
tive databases: HealthCore Integrated Research Da-
tabase (HIRD), IMS LifeLink Health Plan Claims
Database (IMS LifeLink), Premier Perspective Data-
base (PPD), and Wolters Kluwer Pharma Solutions
(WKPS). These 4 databases were selected because
December 2012they are large and capture administrative claims data
at a national level. Infusion data are captured from
the most common sites of care—in-office infusion
suites in physicians’ offices and hospital outpatient
departments. These databases allowed the evalua-
tion of patients receiving infliximab from the follow-
ing perspectives: (1) the nationally representative,
commercially insured population and (2) the hospi-
tal outpatient.
The HIRD has longitudinal medical and phar-
macy claims for 33 million members of 14 com-
mercial health insurance plans in the southeastern,
mid-Atlantic, central, and western United States.
These 14 health plans include health maintenance
organizations, point-of-service plans, preferred-pro-
vider organizations, and indemnity plans. IMS Life-
Link comprises commercial health plan information
for 70 million members obtained from 100 man-
ged care plans in the United States. The WKPS da-
abase integrates US health care claims data from
hysician practices, pharmacies, and hospitals for a
ongitudinal view of health care delivery and usage
atterns for 115 million members.
The PPD is a large US hospital-based, service-level,
all-payer, comparative database containing informa-
tion on 5.5 million annual hospital discharges (ap-
proximately one sixth of all hospitalizations in the
United States) from primarily nonprofit, nongovern-
mental, community, and teaching hospitals as well as
health systems. The Premier data include hospitaliza-
tions from600 hospitals for the period from 2000 to
present.
Patient inclusion and exclusion criteria varied only
slightly across the databases and are detailed in the
Table. The following general criteria were applied to
each of the 4 databases: patients were aged 18 years
at index infliximab claim, were diagnosed with RA
(International Classification of Diseases, 9th Revision,
Clinical Modification [ICD-9-CM] diagnostic code
714.xx), had a 6- to 12-month period without biologic
use prior to initiating infliximab, and were persistent
with infliximab for a select period of time. Patients
with other selected inflammatory diseases, as identified
by ICD-9-CM diagnosis codes, were excluded. The ex-
cluded inflammatory diseases were ankylosing spondy-
litis (720.0), Crohn’s disease (555.xx), psoriasis
(696.1), psoriatic arthritis (696.0), and ulcerative coli-
tis (556.xx).
2287
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In each database, treatment with infliximab was
identified from claims containing the Healthcare Com-
mon Procedure Coding System code for infliximab
(J1745). Dosing was defined as the total number of
milligrams infused at a single infusion event for the
induction (infusions 1–3) and maintenance (infusions
4–12) periods. In HIRD and IMS LifeLink, the dose
was derived by dividing the allowed cost by the whole-
sale acquisition cost (WAC) of infliximab at the time of
the claim. In PPD, the dose was calculated from the
number of 100-mg infliximab vials billed per infusion.
In WKPD, the dose was calculated from the number of
service units charged, where 1 unit 100 mg. Infusion
intervals were calculated as the number of days be-
tween a given infliximab infusion and the subsequent
infusion.
Infliximab dosing and infusion intervals were an-
alyzed in each database for the first 12 infusions,
including both the induction and maintenance peri-
ods. The first 12 infusions were chosen because they
Table. Inclusion and exclusion criteria for selected da
Criteria HIRD
Inclusion criteria
Dates for index infliximab
claim
7/2004–10/2008 1/2
Database enrollment 6 mo preindex, 12 mo
postindex
6 m
pos
Age at index infliximab claim 18 y 1
RA diagnosis 2 Claims 2
Period prior to index infliximab
claim
6 mo with no evidence
of abatacept,
adalimumab,
etanercept, infliximab,
or rituximab
6 m
of a
ada
eta
or r
Persistence Infliximab claim at
index plus 1 claim
365 days postindex
Infl
ind
3
Exclusion criteria
Selected inflammatory diseases Yes Yes
Other exclusion criteria Patients with infliximab
pharmacy claims;
evidence of switching
to another biologic
postindex
Evi
fro
ano
pos
HIRD  HealthCore Integrated Research Database; IMS LifeLink 
Database; RA  rheumatoid arthritis; WKPS Wolters Kluwer Pharepresent the first 18 months of treatment. After
2288the first 12 infusions, sample sizes became small
due to loss to follow-up within each database over
time.
Statistical Analyses
All analyses were conducted separately within each
of the 4 databases. Descriptive analyses were con-
ducted for patient demographic characteristics as well
as for dosing and infusion intervals. The mean (SD)
dose at each infusion andmean (SD) days between each
infusion were calculated within each database. Also,
changes in dose from the first infusion of the induction
period to the highest maintenance dose and from the
first infusion of the maintenance period to the highest
maintenance dose were calculated.
RESULTS
Across the 4 databases, a total of 17,301 patients with
RA using infliximab were identified. Of these, 938
(5%) were from HIRD, 1089 (6%) were from IMS
LifeLink, 2185 (13%) were from PPD, and 13,089
ses.
LifeLink PPD WKPS
2/2007 7/2000–03/2008 1/2004–12/2007
ndex, 12 mo 6 mo preindex, no
required postindex
12 mo preindex, 24 mo
postindex
18 y 18 y
s 1 On-infusion claim 2 Claims
no evidence
ept,
ab,
t, infliximab,
ab
6 mo with no evidence
of infliximab in the
hospital outpatient
setting
12 mo with no evidence
of abatacept,
adalimumab,
etanercept, infliximab,
or rituximab
claim at
1 claim
ostindex
3 doses within 56
d of index infusion
Infliximab claim at
index plus 1 claim
past 730 d; 3 distinct
claims plus index
Yes Yes
f switching
imab to
iologic
— Evidence of switching
from infliximab to
another biologic
postindex; non-
Hodgkin’s lymphoma
LifeLink Health Plan Claims Database; PPD  Premier Perspective
olutions.taba
IMS
004–1
o prei
tindex
8 y
Claim
o with
batac
limum
nercep
ituxim
iximab
ex plus
65 d p
dence o
m inflix
ther b
tindex
IMS
rma S(76%) were from WKPS. Due to study differences in
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HIRD and WKPS sample sizes did not decline until
infusion 5. At infusion 12, 60% to 75% of the sample
remained in the HIRD, IMS LifeLink, and WKPS da-
tabases. In the PPD, which did not have a postindex
time requirement, only 29% of the sample remained at
infusion 12. The majority of patients in all databases
were female (73% in HIRD, 75% in IMS LifeLink,
79% in PPD, and 78% in WKPS). Mean patient age
was 60 years in all databases (59, 58, 60, and 61
years, respectively).
Figure 1 summarizes infliximab dosing for the first 12
infusionswithin eachof the4databases.Observeddosing
patterns from the HIRD, IMS LifeLink, PPD, andWKPS
database were fairly consistent. The mean (SD) doses ad-
ministered at the first induction infusion (infusion 1)were
308.0 (149.0), 345.9 (185.8), 338.2 (156.8), and 336.0
(128.8) mg, respectively. The mean (SD) doses adminis-
tered at the first maintenance infusion (infusion 4) were
332.4 (135.9), 384.9 (200.6), 351.3 (149.6), and 363.5
(138.5)mg. In all 4 databases, the highestmean (SD) dose
wasobserved at infusion12.Thehighestmean (SD)doses
were 401.5 (162.2), 449.2 (240.3), 397.0 (169.8), and
409.2 (155.0) mg. There were minimal dose increases
from the first induction infusion (infusion 1) to the
highest maintenance dose (93.5, 103.3, 58.8, and
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Figure 1. Infliximab dosing at each infusion within
selected databases. HIRDHealthCore
Integrated Research Database; IMS Life-
Link  IMS LifeLink Health Plan Claims
Database; PPD  Premier Perspective
Database; WKPS  Wolters Kluwer
Pharma Solutions.73.2 mg) and from the first maintenance infusion
December 2012(infusion 4) to the highest maintenance dose (69.1,
64.3, 45.7, and 45.7 mg).
Figure 2 summarizes infliximab infusion intervals,
measured as the number of days between infusions, for
the first 12 infusions within each of the 4 databases.
Intervals between infliximab infusions were consistent
across observations in the HIRD, IMS LifeLink, PPD,
andWKPS databases. Within individual databases, the
mean (SD) number of days between infusions in the
maintenance period (intervals 3–4 through intervals
11–12) ranged from 53.3 (23.0) to 63.5 (65.5) days,
53.7 (23.8) to 60.3 (43.4) days, 53.4 (20.3) to 59.4
(26.3) days, and 52.3 (14.6) to 55.0 (16.4) days,
respectively.
DISCUSSION
Because of the extent of flexibility in infliximab dosing
and infusion intervals, there has been increasing inter-
est in understanding the magnitude of infliximab dos-
ing patterns in patients with RA in clinical practice.
The findings from the present study suggest that the
dosing patterns observed across 4 different large US
databases were consistent with FDA-approved pre-
scribing information. Infliximab dosing and infusion
intervals were observed to have been relatively consis-
tent for the first 12 infusions.
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Figure 2. Infliximab infusion intervals within se-
lected databases. HIRD  HealthCore
Integrated Research Database; IMS Life-
Link  IMS LifeLink Health Plan Claims
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Database; WKPS  Wolters Kluwer
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Clinical TherapeuticsIn the literature, some studies of infliximab dosing
patterns have reported only the percentage of patients
with a dose increase in a given time period.9–13 These
imited data, however, do not have enough detail to
ssess the magnitude of dose increase. Results of the
urrent study demonstrated infliximab dose increases
ver time, but the increase within each of the 4 data-
ases was minimal. During the first 12 infusions, the
oses were increased, on average, by 93.5, 103.3, 58.8,
nd 73.2 mg in the HIRD, IMS LifeLink, PPD, and
KPS databases, respectively. There was a 100-mg
1-vial) dose increase observed from the first induction
nfusion to the highest observed maintenance dose ad-
inistered to patients over 12 infusions, regardless of the
elected database.
The mean infliximab dosing at each infusion across
hese databases was consistent with those reported in
ther analyses of claims data.7–8 Due to the nature of
claims data, however, studies that use administrative
databases, including the present study, may overesti-
mate the actual use of infliximab in clinical practice.
Infliximab is dispensed in single-use, 100-mg vials. Al-
though only a partial vial may be needed to achieve
appropriate dosing in clinical practice, payments are
made for the entire vial, including any wastage. Claims
contained within the database reflected payments and
therefore assumed full vial usage without any wastage.
Assuming that a 100-mg dose increase occurred, on
average, at infusion 6 and that the current infliximab
WAC is US $690.11 per 100-mg vial (Analysource/
First DataBank, March 8, 2011), there is an additional
cost of $4140.66 (6 infusions  $690.11 WAC) per
patient over 12 infusions or the first 18 months of
therapy. Assuming 3 vials (300 mg) for infusions 1
through 5 and 4 vials (400 mg) for infusions 6 through
12, dose increases account for only 16.3% of the esti-
mated total treatment costs of infliximab over this pe-
riod of 18 months. Furthermore, the infusion inter-
val during the maintenance period was 8 weeks.
Previous research has also demonstrated that ad-
justments in dosing patterns more often include a dose
increase rather than any shortening of infusion inter-
vals.4 Results from this multidatabase study corrobo-
ate with those from prior reports in the literature.6–13
Observed infusion intervals in the maintenance period
were very close to the 8-week (56-day) FDA-approved
prescribing recommendation. Maintenance infusion
intervals ranged from 52.3 to 63.5 days, on average,
across the 4 databases.
2290This study evaluated data from a total of 17,301
patients with RA using infliximab across 4 large US
administrative databases: HIRD, IMS LifeLink, PPD,
and WKPS database. Observed infliximab dosing pat-
terns and infusion intervals were consistent across the
4 databases. Also, infliximab-treated patients within
each of the 4 databases were predominantly female and
older, which is consistent with the higher prevalence of
RA in these populations.14 The large sample size and
expected demographic distributions based on accepted
prevalence estimates support the generalizability of
these results to the US population of patients with RA
using infliximab. The consistency of results across mul-
tiple databases, even with differing patient popula-
tions, demonstrate that these results are not merely the
artefact of a single data source and further support the
generalizability of the study results.
Study Limitations
Data from the present study were taken from ad-
ministrative databases. Because the primary purpose of
these databases is the submission and payment of
claims for health care services, only data directly appli-
cable for these purposes were available. Patients’
weights for calculating dosing by weight were not
available in any of the 4 databases, nor were other
clinical measures ormetrics of disease activity or health
status. Infliximab utilization is derived from an esti-
mate of vial usage based on “allowable” charge
amounts and WAC cost per unit from 2 of the data-
bases and number of vials or service units charged in
the other 2 databases. Without the knowledge of or
ability to calculate dosing by weight, the interpretabil-
ity of dosing was limited to evaluating themean change
in overall utilization. Based on data from the 2010 US
National Health and Wellness Survey,15 the median
weight of a patient diagnosed with RA was 81.6 kg.
Assuming for simplicity that a patient with RA weighs
80 kg, on average, the dose increase over 12 infu-
sions would range from 0.74 to 1.29mg/kg. Also, eval-
uations of clinical response, reasons for changes in dos-
ing or infusion intervals, and dosing-related outcomes
could not be assessed.
Only 3 (HIRD, IMS LifeLink, and WKPS) of the 4
databases required patients to persist on infliximab
therapy for a set time period, and the required time
period varied by database. As a result of these varying
persistence requirements, the data may not be fully
comparable across the databases. Patients who were
Volume 34 Number 12
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their infliximab doses increased, or who were discon-
tinued from biologic therapy instead of continued on
the infliximab dose, were not included in the present
analysis. Additionally, the present study included only
the first 12 infusions because sample sizes became
small due to loss of follow-up within databases over
time. These first 12 infusions may not have fallen
within the persistence requirement for all patients,
so an additional number of patients may have been
lost from the databases, which may have influenced
the results. Also, it was not possible to assess
whether dosing and infusion intervals remained con-
sistent after infusion 12.
This study describes dosing trends within 4 separate
administrative databases. These databases may have
different patient populations and different methods for
ensuring data capture and quality. Sex and age distri-
butions were similar across the databases, but other
patient characteristics may not have been captured,
which may have affected the study results in unin-
tended ways. Also, while inclusion and exclusion cri-
teria were similar across the databases, some slight dif-
ferences were evident, which may have affected the
study results. Therefore, these 4 databases are not di-
rectly comparable, and indirect comparisons should be
interpreted with caution.
CONCLUSIONS
Data across multiple large US databases suggest that,
in clinical practice, infliximab dosing and infusion in-
tervals in patients with RA for the first 12 infusions,
which represent the first 18 months of treatment,
ere consistent with FDA prescribing recommenda-
ions. Any infliximab dose change appears to be pre-
ominantly due to dose increases versus shortening of
he infusion interval. The mean overall infliximab dose
scalation over the 12-infusion treatment period stud-
ed resulted in 16.3% variation from the expected
reatment costs (ie, treatment costs with no dose
ncreases).
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